Genetic Disorders · Gaucher DiseaseTrial Updateclinicalmid-term

Phase 1/2 Trial of LY3884961 for Gaucher Disease Initiated by Prevail Therapeutics

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Eli Lilly74 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/14/2026, 6:04:40 AM

Assessment confidence: 67% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the Phase 1/2 trial for LY3884961 by Prevail Therapeutics represents a significant development in the treatment landscape for Gaucher Disease. This could shift competitive dynamics and influence investment strategies in genetic disorder therapies. Regulatory context from FDA (FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)) supports the near-term read. Assessment grounded in 15 ranked evidence items (7 high-relevance).

Strategic Assessment

The initiation of this trial may influence strategic decisions regarding investment in Gaucher Disease therapies and partnerships. The strongest clinical anchor is Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders (ClinicalTrials.gov), sub-indication match (rare disease); sponsor/company relevance (lilly). In rare disease, 6 regulatory and 1 competitive items passed relevance filtering for Prevail Therapeutics.

Competitive Pressure

The most relevant competitive pressure comes from Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation (Humanexa Signals) — sponsor/company relevance (lilly). This trial positions Prevail Therapeutics and its collaboration with Eli Lilly in the competitive landscape of Gaucher Disease treatments, potentially impacting existing therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG) (FDA). Sub-indication match (rare disease); Sponsor/company relevance (Lilly). The trial's progress will be closely watched for implications on future regulatory approvals and labeling for Gaucher Disease therapies, impacting compliance and market entry strategies.

Key Risks

Elevated medium regulatory exposure for Prevail Therapeutics could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The trial's outcomes may affect market share and competitive positioning for existing Gaucher Disease treatments, potentially leading to shifts in revenue streams depending on the trial's success.
Upside for Prevail Therapeutics may improve if A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Prevail Therapeutics may improve if A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB) (ClinicalTrials.gov) delivers favorable follow-through.
The initiation of this trial may influence strategic decisions regarding investment in Gaucher Disease therapies and partnerships.

What Would Change This Assessment

This becomes more urgent if Monitor patient enrollment progress and initial safety and efficacy data over the next 18 months.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Sponsor/company relevance (Lilly)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Sponsor/company relevance (Lilly)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Sponsor/company relevance (Lilly)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Sponsor/company relevance (Lilly)
FDA document
View source
Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
FDAhigh relevance
Sub-indication match (rare disease); Sponsor/company relevance (Lilly)
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAhigh relevance
Sub-indication match (rare disease); Sponsor/company relevance (Lilly)
FDA document
View source

Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
ClinicalTrials.govhigh relevance
Sub-indication match (rare disease); Sponsor/company relevance (Lilly)
FDA document
View source
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
ClinicalTrials.govmedium relevance
Entity match (prevail therapeutics)
FDA document
View source
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Lilly)
FDA document
View source

Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation
Humanexa Signalsmedium relevance
Sponsor/company relevance (Lilly)

Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedmedium relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Sponsor/company relevance (Lilly)
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Peer-delivered combined EMD and imagery rescripting for traumatized Chinese university students: RCT.
PubMedmedium relevance
Sponsor/company relevance (Lilly)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Prevail Therapeutics
Eli Lilly
Gaucher Disease therapies

Commercial impact

medium

The trial's outcomes may affect market share and competitive positioning for existing Gaucher Disease treatments, potentially leading to shifts in revenue streams depending on the trial's success.

Regulatory impact

medium

The trial's progress will be closely watched for implications on future regulatory approvals and labeling for Gaucher Disease therapies, impacting compliance and market entry strategies.

What to watch

Monitor patient enrollment progress and initial safety and efficacy data over the next 18 months.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.